The COL8A2 antibody targets collagen type VIII alpha 2 chain (COL8A2), a component of type VIII collagen, a short-chain collagen primarily found in basement membranes and extracellular matrices. COL8A2 is critical for maintaining tissue integrity, particularly in vascular and ocular structures. It plays a role in endothelial cell adhesion, migration, and angiogenesis. Mutations in the COL8A2 gene are linked to corneal dystrophies, such as posterior polymorphous corneal dystrophy (PPCD) and Fuchs' endothelial corneal dystrophy (FECD), highlighting its importance in corneal endothelial function. COL8A2 antibodies are widely used in research to study its expression, localization, and pathological mechanisms in these diseases. They enable detection via techniques like immunohistochemistry, Western blotting, and immunofluorescence, aiding in understanding COL8A2's interaction with other extracellular matrix proteins and signaling pathways. Additionally, these antibodies help explore COL8A2's potential role in cancer progression and fibrosis, as aberrant expression has been observed in tumor vasculature and fibrotic tissues. Commercial COL8A2 antibodies are typically raised in hosts like rabbits or mice, with validation in knockout models or siRNA-treated cells to ensure specificity. Their applications extend to diagnostic development and therapeutic targeting, particularly in ocular and vascular disorders.